Single Patient Investigational Treatment for Cree Leukoencephalopathy
This study focuses on Cree Leukoencephalopathy (CLE), a very rare and severe brain disease mainly affecting people from Cree communities in Northern Quebec. This condition causes the brain's white matter, essential for nerve communication, to slowly break down, leading to serious health problems and unfortunately, early death. Currently, there are no effective treatments for CLE. This study is looking at a new medicine called fosigotifator, which is also being tested for a similar condition. The main goal is to offer this new drug to a patient with CLE who has no other treatment options. Researchers want to see if the drug can help slow down or stop the brain damage and improve the patient's symptoms and overall quality of life.
At a glance
What is this study about?
Cree Leukoencephalopathy (CLE) is a very rare and serious brain disease. It mostly affects children in Cree communities in Northern Quebec. This condition causes the white matter in the brain – which is like the wiring that helps different parts of your brain talk to each other – to slowly get damaged. As this damage progresses, children develop severe problems with their movement and thinking, which unfortunately get worse over time and lead to a short life.
At the moment, there aren't any medicines that can effectively treat CLE. We know that CLE is caused by a small change in a specific gene, called EIF2B5. This is the same gene that's involved in another similar brain condition called Vanishing White Matter (VWM). Because the underlying cause is similar, a new drug called fosigotifator, which is currently being studied for VWM, might also help patients with CLE.
This study aims to provide this new, investigational drug, fosigotifator, to a patient with CLE/VWM who has no other treatment choices. The doctors will carefully watch to see if this drug can help slow down or stop the brain's white matter from getting worse. They also want to understand if the possible good effects of the drug are greater than any potential side effects. By targeting the root cause of the disease, the hope is that fosigotifator could help reduce the patient's symptoms and improve their overall quality of life.
Key takeaways
- This study is for Cree Leukoencephalopathy (CLE), a very rare brain condition with no current cure.
- It tests a new drug called fosigotifator, which targets the genetic cause of the disease.
- The goal is to see if the drug can slow or stop brain damage and improve a patient's health.
- Participation requires a confirmed CLE diagnosis and parental consent.
- This study offers a potential new treatment option where none currently exist.
Who may be eligible?
To be able to take part in this study, the patient must have a confirmed diagnosis of Cree Leukoencephalopathy (CLE) based on genetic tests. They should either not have symptoms yet, or only have very early symptoms of the condition.
The patient's parents or legal guardians must agree to their child being part of the study and provide their signed permission. The patient must also be at least one month old and weigh at least 5 kilograms (about 11 pounds) when they start the study. Importantly, they cannot be already taking part in another study for this drug.
There are no specific reasons listed that would stop someone from joining the study, other than not meeting the 'inclusion' criteria mentioned above.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Has a doctor confirmed a diagnosis of Cree Leukoencephalopathy (CLE) with genetic tests?
- Is the patient showing no symptoms yet, or only very early symptoms?
- Is the patient at least 1 month old?
- Does the patient weigh at least 5 kilograms (about 11 pounds)?
- Is the patient *not* currently taking part in another study for this specific drug?
What does participation involve?
This study involves giving an investigational drug called fosigotifator. The exact details of how often you would need to visit a clinic, what tests would be done, and for how long the treatment would last are not fully described here. However, it's typical for such studies to involve regular check-ups, potentially including brain scans and other assessments, to monitor the patient's health and how the drug is working. You would also have ongoing follow-up care. The overall duration of participation would be explained by the study team.
Potential risks and benefits
Locations (1)
- McGill University Health CentreVerified postcodeMontreal, Canada
Common questions
What is Cree Leukoencephalopathy (CLE)?
CLE is a very rare and severe brain disease that causes the brain's white matter to break down, leading to serious health problems, mainly in children from Northern Quebec's Cree communities.
What is fosigotifator?
Fosigotifator is a new, experimental drug being tested to see if it can help slow down or stop the brain damage caused by conditions like CLE.
Why is this study important?
This study is important because there are currently no effective treatments for CLE, and it offers a potential new option for patients with this severe condition.
Who can join this study?
Patients must have a confirmed diagnosis of CLE, be very young or just starting to show symptoms, be at least 1 month old and weigh at least 5kg, and not be in another study for this drug.
Are there any risks to taking part?
As it's a new drug, potential side effects are not fully known. The research team will discuss all known and potential risks with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.